These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

352 related items for PubMed ID: 16112420

  • 1. Mapping of the methylation pattern of the MUC2 promoter in pancreatic cancer cell lines, using bisulfite genomic sequencing.
    Hamada T, Goto M, Tsutsumida H, Nomoto M, Higashi M, Sugai T, Nakamura S, Yonezawa S.
    Cancer Lett; 2005 Sep 28; 227(2):175-84. PubMed ID: 16112420
    [Abstract] [Full Text] [Related]

  • 2. Mapping the methylation pattern by bisulfite genomic sequencing of the E-cadherin promoter CpG island in nasopharyngeal carcinoma.
    Kao RH, Huang LC, Hsu YH.
    Anticancer Res; 2002 Sep 28; 22(6C):4109-13. PubMed ID: 12553040
    [Abstract] [Full Text] [Related]

  • 3. MUC2 expression is regulated by histone H3 modification and DNA methylation in pancreatic cancer.
    Yamada N, Hamada T, Goto M, Tsutsumida H, Higashi M, Nomoto M, Yonezawa S.
    Int J Cancer; 2006 Oct 15; 119(8):1850-7. PubMed ID: 16721789
    [Abstract] [Full Text] [Related]

  • 4. Methylation analysis of the promoter F of estrogen receptor alpha gene: effects on the level of transcription on human osteoblastic cells.
    Penolazzi L, Lambertini E, Giordano S, Sollazzo V, Traina G, del Senno L, Piva R.
    J Steroid Biochem Mol Biol; 2004 Jun 15; 91(1-2):1-9. PubMed ID: 15261302
    [Abstract] [Full Text] [Related]

  • 5. CpG hypermethylation of promoter region and inactivation of E-cadherin gene in human bladder cancer.
    Ribeiro-Filho LA, Franks J, Sasaki M, Shiina H, Li LC, Nojima D, Arap S, Carroll P, Enokida H, Nakagawa M, Yonezawa S, Dahiya R.
    Mol Carcinog; 2002 Aug 15; 34(4):187-98. PubMed ID: 12203370
    [Abstract] [Full Text] [Related]

  • 6. MUC2 gene suppression in human colorectal carcinomas and their metastases: in vitro evidence of the modulatory role of DNA methylation.
    Hanski C, Riede E, Gratchev A, Foss HD, Böhm C, Klussmann E, Hummel M, Mann B, Buhr HJ, Stein H, Kim YS, Gum J, Riecken EO.
    Lab Invest; 1997 Dec 15; 77(6):685-95. PubMed ID: 9426407
    [Abstract] [Full Text] [Related]

  • 7. DNA methylation analysis of the promoter region of the human telomerase reverse transcriptase (hTERT) gene.
    Devereux TR, Horikawa I, Anna CH, Annab LA, Afshari CA, Barrett JC.
    Cancer Res; 1999 Dec 15; 59(24):6087-90. PubMed ID: 10626795
    [Abstract] [Full Text] [Related]

  • 8. Methylation status of promoters and expression of MUC2 and MUC5AC mucins in pancreatic cancer cells.
    Ho JJ, Han SW, Pan PL, Deng G, Kuan SF, Kim YS.
    Int J Oncol; 2003 Feb 15; 22(2):273-9. PubMed ID: 12527922
    [Abstract] [Full Text] [Related]

  • 9. [Increased methylation of promotor region suppresses expression of MUC2 gene in colon carcinoma cells].
    Riede E, Gratchev A, Foss HD, Mann B, Buhr HJ, Hanski C.
    Langenbecks Arch Chir Suppl Kongressbd; 1998 Feb 15; 115(Suppl I):299-302. PubMed ID: 14518264
    [Abstract] [Full Text] [Related]

  • 10. DNA methylation paradigm shift: 15-lipoxygenase-1 upregulation in prostatic intraepithelial neoplasia and prostate cancer by atypical promoter hypermethylation.
    Kelavkar UP, Harya NS, Hutzley J, Bacich DJ, Monzon FA, Chandran U, Dhir R, O'Keefe DS.
    Prostaglandins Other Lipid Mediat; 2007 Jan 15; 82(1-4):185-97. PubMed ID: 17164146
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Epigenetic modulation of tumor suppressor CCAAT/enhancer binding protein alpha activity in lung cancer.
    Tada Y, Brena RM, Hackanson B, Morrison C, Otterson GA, Plass C.
    J Natl Cancer Inst; 2006 Mar 15; 98(6):396-406. PubMed ID: 16537832
    [Abstract] [Full Text] [Related]

  • 14. Influence of CpG island methylation status in O6-methylguanine-DNA methyltransferase expression of oral cancer cell lines.
    Murakami J, Asaumi J, Maki Y, Tsujigiwa H, Nagatsuka H, Kokeguchi S, Inoue T, Kawasaki S, Tanaka N, MacPhee D, Matsubara N, Kishi K.
    Oncol Rep; 2004 Aug 15; 12(2):339-45. PubMed ID: 15254699
    [Abstract] [Full Text] [Related]

  • 15. Sp1/Sp3 and DNA-methylation contribute to basal transcriptional activation of human podoplanin in MG63 versus Saos-2 osteoblastic cells.
    Hantusch B, Kalt R, Krieger S, Puri C, Kerjaschki D.
    BMC Mol Biol; 2007 Mar 07; 8():20. PubMed ID: 17343736
    [Abstract] [Full Text] [Related]

  • 16. Silencing of HTR1B and reduced expression of EDN1 in human lung cancers, revealed by methylation-sensitive representational difference analysis.
    Takai D, Yagi Y, Wakazono K, Ohishi N, Morita Y, Sugimura T, Ushijima T.
    Oncogene; 2001 Nov 08; 20(51):7505-13. PubMed ID: 11709722
    [Abstract] [Full Text] [Related]

  • 17. Aberrant methylation of the BRCA1 CpG island promoter is associated with decreased BRCA1 mRNA in sporadic breast cancer cells.
    Rice JC, Massey-Brown KS, Futscher BW.
    Oncogene; 1998 Oct 08; 17(14):1807-12. PubMed ID: 9778046
    [Abstract] [Full Text] [Related]

  • 18. IGSF4 promoter methylation and expression silencing in human cervical cancer.
    Li J, Zhang Z, Bidder M, Funk MC, Nguyen L, Goodfellow PJ, Rader JS.
    Gynecol Oncol; 2005 Jan 08; 96(1):150-8. PubMed ID: 15589594
    [Abstract] [Full Text] [Related]

  • 19. Suppression of thymidine phosphorylase expression by promoter methylation in human cancer cells lacking enzyme activity.
    Guarcello V, Blanquicett C, Naguib FN, El Kouni MH.
    Cancer Chemother Pharmacol; 2008 Jun 08; 62(1):85-96. PubMed ID: 17805539
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.